Skip to main content
Figure 3 | BMC Medicine

Figure 3

From: Transforming growth factor β1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): possible mechanism for the failure of BMP therapy?

Figure 3

Recombinant human transforming growth factor β 1 (rhTGFβ 1 ) treatment alters protein levels of phospho-Smad1/5/8, Smad1, TGFβ receptor (TGFβR) and Ski-related novel protein N (SnoN) in primary human osteoblasts. (A) Representative western blot picture of primary human osteoblasts treated with 50 ng/ml recombinant human bone morphogenic protein (rhBMP)-2 or rhBMP-7 ± 5 ng/ml rhTGFβ1 for 72 h. Membranes were probed for phospho-Smad1/5/8, Smad1/2, TGFβR and SnoN. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control. Densitometric analysis (N = 6; n = 6) for (B) phospho-Smad1/5/8, (C) Smad1, (D) TGFβR and (E) SnoN. *P < 0.05; **P < 0.01; ***P < 0.001 as compared to untreated cells. °°P < 0.01; °°°P < 0.001.

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us